Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma.

Kelong Han Melanie Ren Wolfgang Wick Lauren Abrey Asha Das Jin Jin David A Reardon

Neuro Oncol

Genentech, South San Francisco, California (K.H., A.D., J.J.); Stanford University, Palo Alto, California (M.R.); University Medical Center & DKFZ, Heidelberg, Germany (W.W.); F. Hoffmann-La Roche, Basel, Switzerland (L.A.); Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts (D.A.R.).

Published: May 2015

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386660	PMC
http://dx.doi.org/10.1093/neuonc/nov021	DOI Listing

Publication Analysis

Top Keywords

interpretation meta-analysis

meta-analysis evaluating

evaluating progression-free

progression-free survival

survival surrogate

surrogate endpoint

endpoint survival

survival glioblastoma

survival

interpretation

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!